[HTML][HTML] Comorbidities, multimorbidity and COVID-19
The influence of comorbidities on COVID-19 outcomes has been recognized since the
earliest days of the pandemic. But establishing causality and determining underlying …
earliest days of the pandemic. But establishing causality and determining underlying …
[HTML][HTML] Risk of mortality in HIV-infected COVID-19 patients: a systematic review and meta-analysis
T Dzinamarira, G Murewanhema, I Chitungo… - Journal of Infection and …, 2022 - Elsevier
Background The relationship between HIV infection and COVID-19 clinical outcomes
remains a significant public health research problem. We aimed to determine the …
remains a significant public health research problem. We aimed to determine the …
Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort …
Background In rituximab-treated patients with rheumatoid arthritis, humoral and cellular
immune responses after two or three doses of SARS-CoV-2 vaccines are not well …
immune responses after two or three doses of SARS-CoV-2 vaccines are not well …
Remdesivir resistance in transplant recipients with persistent coronavirus disease 2019
JI Hogan, R Duerr, D Dimartino, C Marier… - Clinical Infectious …, 2023 - academic.oup.com
New mutations conferring resistance to SARS-CoV-2 therapeutics have important clinical
implications. We describe the first cases of an independently acquired V792I RNA …
implications. We describe the first cases of an independently acquired V792I RNA …
[HTML][HTML] Outcome of COVID-19 in hospitalised immunocompromised patients: An analysis of the WHO ISARIC CCP-UK prospective cohort study
Background Immunocompromised patients may be at higher risk of mortality if hospitalised
with Coronavirus Disease 2019 (COVID-19) compared with immunocompetent patients …
with Coronavirus Disease 2019 (COVID-19) compared with immunocompetent patients …
Breakthrough SARS-CoV-2 infections with the delta (B. 1.617. 2) variant in vaccinated patients with immune-mediated inflammatory diseases using …
L Boekel, EW Stalman, L Wieske… - The Lancet …, 2022 - thelancet.com
Background Concerns have been raised regarding the risks of SARS-CoV-2 breakthrough
infections in vaccinated patients with immune-mediated inflammatory diseases treated with …
infections in vaccinated patients with immune-mediated inflammatory diseases treated with …
[HTML][HTML] COVID-19 vaccine effectiveness against omicron (B. 1.1. 529) variant infection and hospitalisation in patients taking immunosuppressive medications: a …
Background There is a scarcity of research regarding the effectiveness of the mRNA-1273
(Moderna) and BNT162b2 (Pfizer-BioNTech) COVID-19 vaccines in patients taking …
(Moderna) and BNT162b2 (Pfizer-BioNTech) COVID-19 vaccines in patients taking …
Interplay of immunosuppression and immunotherapy among patients with cancer and COVID-19
Importance Cytokine storm due to COVID-19 can cause high morbidity and mortality and
may be more common in patients with cancer treated with immunotherapy (IO) due to …
may be more common in patients with cancer treated with immunotherapy (IO) due to …
Rituximab is associated with worse COVID-19 outcomes in patients with rheumatoid arthritis: a retrospective, nationally sampled cohort study from the US National …
Objective To assess whether rituximab (RTX) is associated with worse COVID-19 outcomes
among patients with rheumatoid arthritis (RA). Methods We used the National COVID Cohort …
among patients with rheumatoid arthritis (RA). Methods We used the National COVID Cohort …
Breakthrough SARS–CoV‐2 Infections in Patients With Immune‐Mediated Disease Undergoing B Cell–Depleting Therapy: A Retrospective Cohort Analysis
CM Calabrese, E Kirchner, EM Husni… - Arthritis & …, 2022 - Wiley Online Library
Objective Patients with immune‐mediated inflammatory diseases (IMIDs) receiving B cell–
depleting therapy (BCDT) are among the most vulnerable to severe COVID‐19, as well as …
depleting therapy (BCDT) are among the most vulnerable to severe COVID‐19, as well as …